Literature DB >> 18332481

Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics.

Brooke B Ancrile1, Kevin M O'Hayer, Christopher M Counter.   

Abstract

The Ras family of small guanosine triphosphatases normally transmit signals from cell surface receptors to the interior of the cell. Stimulation of cell surface receptors leads to the activation of guanine exchange factors, which, in turn, convert Ras from an inactive GDP-bound state to an active GTP-bound state. However, in one third of human cancers, RAS is mutated and remains in the constitutively active GTP-bound state. In this oncogenic state, RAS activates a constellation of signaling that is known to promote tumorigenesis. One consequence of this oncogenic RAS signal in cancer cells is the upregulation of the cytokines interleukin (IL)-6, IL-8, and chemokine growth-regulated oncogene 1 (GRO-1). We review the evidence supporting a role for these cytokines in oncogenic RAS-driven solid tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332481      PMCID: PMC2788125          DOI: 10.1124/mi.8.1.6

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  43 in total

1.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

Authors:  G H Fisher; S L Wellen; D Klimstra; J M Lenczowski; J W Tichelaar; M J Lizak; J A Whitsett; A Koretsky; H E Varmus
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

2.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.

Authors:  S F Shariat; B Andrews; M W Kattan; J Kim; T M Wheeler; K M Slawin
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

3.  Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency.

Authors:  S H Jee; S C Shen; H C Chiu; W L Tsai; M L Kuo
Journal:  Oncogene       Date:  2001-01-11       Impact factor: 9.867

4.  Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.

Authors:  J Rak; Y Mitsuhashi; C Sheehan; A Tamir; A Viloria-Petit; J Filmus; S J Mansour; N G Ahn; R S Kerbel
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

Review 5.  The Ras family of GTPases in cancer cell invasion.

Authors:  R Hernández-Alcoceba; L del Peso; J C Lacal
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

6.  Elevation of cytokine levels in cachectic patients with prostate carcinoma.

Authors:  Jesco Pfitzenmaier; Robert Vessella; Celestia S Higano; Jennifer L Noteboom; David Wallace; Eva Corey
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

7.  Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer.

Authors:  S J Wigmore; K C H Fearon; K Sangster; J P Maingay; O J Garden; J A Ross
Journal:  Int J Oncol       Date:  2002-10       Impact factor: 5.650

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

Authors:  Brooke Ancrile; Kian-Huat Lim; Christopher M Counter
Journal:  Genes Dev       Date:  2007-07-15       Impact factor: 11.361

Review 10.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

View more
  46 in total

1.  IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines.

Authors:  Katherine M Block; Neale T Hanke; Erin A Maine; Amanda F Baker
Journal:  Pancreas       Date:  2012-07       Impact factor: 3.327

Review 2.  Pancreatic cancer, inflammation, and microbiome.

Authors:  Constantinos P Zambirinis; Smruti Pushalkar; Deepak Saxena; George Miller
Journal:  Cancer J       Date:  2014 May-Jun       Impact factor: 3.360

3.  Dysregulation of janus kinases and signal transducers and activators of transcription in cancer.

Authors:  Ana P Costa-Pereira; Nair A Bonito; Michael J Seckl
Journal:  Am J Cancer Res       Date:  2011-06-22       Impact factor: 6.166

4.  miR-526a regulates apoptotic cell growth in human carcinoma cells.

Authors:  Xiaoli Yang; Cui Wang; Changzhi Xu; Zhifeng Yan; Congwen Wei; Kai Guan; Shengli Ma; Ye Cao; Liping Liu; Deyong Zou; Xiang He; Buchang Zhang; Qingjun Ma; Zirui Zheng
Journal:  Mol Cell Biochem       Date:  2015-05-23       Impact factor: 3.396

Review 5.  Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.

Authors:  C R Balistreri; G Candore; D Lio; G Carruba
Journal:  Cancer Gene Ther       Date:  2014-01-10       Impact factor: 5.987

6.  KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation.

Authors:  Faraz Bishehsari; Lijuan Zhang; Usman Barlass; Nailliw Z Preite; Sanja Turturro; Matthew S Najor; Brandon B Shetuni; Janet P Zayas; Mahboobeh Mahdavinia; Abde M Abukhdeir; Ali Keshavarzian
Journal:  Int J Cancer       Date:  2018-08-09       Impact factor: 7.396

7.  Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.

Authors:  K Hayashi; Y Momoi; N Tanuma; A Kishimoto; H Ogoh; H Kato; M Suzuki; Y Sakamoto; Y Inoue; M Nomura; H Kiyonari; M Sakayori; K Fukamachi; Y Kakugawa; Y Yamashita; S Ito; I Sato; A Suzuki; M Nishio; M Suganuma; T Watanabe; H Shima
Journal:  Oncogene       Date:  2014-12-08       Impact factor: 9.867

8.  Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).

Authors:  Andrew B Nixon; Herbert Pang; Mark D Starr; Paula N Friedman; Monica M Bertagnolli; Hedy L Kindler; Richard M Goldberg; Alan P Venook; Herbert I Hurwitz
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

Review 9.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 10.  Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Authors:  Alessia Bottos; Alberto Bardelli
Journal:  Cell Mol Life Sci       Date:  2013-05-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.